1. Home
  2. ACRV vs BTOC Comparison

ACRV vs BTOC Comparison

Compare ACRV & BTOC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ACRV
  • BTOC
  • Stock Information
  • Founded
  • ACRV 2018
  • BTOC 2020
  • Country
  • ACRV United States
  • BTOC United States
  • Employees
  • ACRV N/A
  • BTOC N/A
  • Industry
  • ACRV Medicinal Chemicals and Botanical Products
  • BTOC
  • Sector
  • ACRV Health Care
  • BTOC
  • Exchange
  • ACRV Nasdaq
  • BTOC Nasdaq
  • Market Cap
  • ACRV 40.4M
  • BTOC 48.3M
  • IPO Year
  • ACRV 2022
  • BTOC 2024
  • Fundamental
  • Price
  • ACRV $1.34
  • BTOC $1.60
  • Analyst Decision
  • ACRV Buy
  • BTOC
  • Analyst Count
  • ACRV 7
  • BTOC 0
  • Target Price
  • ACRV $17.60
  • BTOC N/A
  • AVG Volume (30 Days)
  • ACRV 379.9K
  • BTOC 28.0K
  • Earning Date
  • ACRV 08-12-2025
  • BTOC 05-16-2025
  • Dividend Yield
  • ACRV N/A
  • BTOC N/A
  • EPS Growth
  • ACRV N/A
  • BTOC N/A
  • EPS
  • ACRV N/A
  • BTOC N/A
  • Revenue
  • ACRV N/A
  • BTOC $184,757,071.00
  • Revenue This Year
  • ACRV N/A
  • BTOC $30.78
  • Revenue Next Year
  • ACRV N/A
  • BTOC $17.61
  • P/E Ratio
  • ACRV N/A
  • BTOC N/A
  • Revenue Growth
  • ACRV N/A
  • BTOC 8.83
  • 52 Week Low
  • ACRV $1.05
  • BTOC $0.80
  • 52 Week High
  • ACRV $10.16
  • BTOC $8.74
  • Technical
  • Relative Strength Index (RSI)
  • ACRV 55.88
  • BTOC N/A
  • Support Level
  • ACRV $1.15
  • BTOC N/A
  • Resistance Level
  • ACRV $1.38
  • BTOC N/A
  • Average True Range (ATR)
  • ACRV 0.09
  • BTOC 0.00
  • MACD
  • ACRV 0.02
  • BTOC 0.00
  • Stochastic Oscillator
  • ACRV 83.33
  • BTOC 0.00

About ACRV Acrivon Therapeutics Inc.

Acrivon Therapeutics Inc is a clinical-stage biopharmaceutical company developing oncology medicines that the Firm matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's pipeline includes the Phase 2 lead program, ACR-368, referred to as prexasertib, a targeted oncology asset, as well as preclinical stage pipeline programs targeting critical nodes in the DNA Damage Response and cell cycle regulation pathways, including WEE1, a protein kinase, and PKMYT1, a closely related protein serine/threonine kinase.

About BTOC Armlogi Holding Corp. Common Stock

Armlogi Holding Corp is a fast-growing U.S.-based warehousing and logistics service provider that offers a comprehensive package of supply-chain solutions relating to warehouse management and order fulfillment. The company provides one-stop warehousing and logistics services to cross-border e-commerce merchants outside the U.S. who seek to sell in the U.S. market. The warehouses are equipped with automated sorting systems, heavy-duty forklifts, and pallets and trays that are suitable for processing bulky items. The services of the company include customs brokerage services, transportation of merchandise to U.S. warehouses, and warehouse management and order fulfillment services.

Share on Social Networks: